Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review

2012 ◽  
Vol 12 (8) ◽  
pp. 1033-1043 ◽  
Author(s):  
Asmaa Al-Allak ◽  
Paul D Lewis ◽  
Gianfilippo Bertelli
2003 ◽  
Vol 17 (2) ◽  
pp. 117-136 ◽  
Author(s):  
Lea M. Budden ◽  
Penny F. Pierce ◽  
Barbara A. Hayes ◽  
Petra G. Buettner

Women diagnosed with early breast cancer are now asked by their doctors to choose from a range of options for their preferred medical treatment plan. Little information is known about women’s treatment decision-making and therefore nurses do not have evidence to guide this decision support. The aim of this descriptive survey was to investigate the prediagnostic decision-making behavior of a sample (N= 377) of Australian women, regarding their treatment choices for early breast cancer. The data were collected using the Pre-Decision Portfolio Questionnaire (PDPQ) by Pierce (1996), which includes the Michigan Assessment of Decision Styles (MADS). Of 366 participating women, 19.9% strongly agreed to all three items of the MADS factor Deferring Responsibility; 0.3% strongly agreed to all four factors of Avoidance; 32.7% strongly agreed on all four items of Information Seeking; and 63.4% strongly agreed to all five items of Deliberation. Women showed a variety of preferred decision styles, depending on age, education, occupation and employment status. Only 36% of women indicated it was critically important to “get the treatment over as soon as possible;” 55% to “participate in selecting treatment;” and 53% to “read a lot of information.” The understanding of factors that are important to women when they are making decisions for medical treatment is a mandatory step in designing customized evidence-based decision support, which can be delivered by nurses to help women during this distressing experience.


2020 ◽  
Vol 27 (17) ◽  
pp. 2826-2839 ◽  
Author(s):  
Roberta Caputo ◽  
Daniela Cianniello ◽  
Antonio Giordano ◽  
Michela Piezzo ◽  
Maria Riemma ◽  
...  

The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).


2021 ◽  
pp. 102229
Author(s):  
Christian Jackisch ◽  
Patricia Cortazar ◽  
Charles E. Geyer Jr ◽  
Luca Gianni ◽  
Joseph Gligorov ◽  
...  

2017 ◽  
Vol 26 (12) ◽  
pp. 2094-2100 ◽  
Author(s):  
Maria Burton ◽  
Karen Kilner ◽  
Lynda Wyld ◽  
Kate Joanna Lifford ◽  
Frances Gordon ◽  
...  

2002 ◽  
Vol 38 (6) ◽  
pp. 745-749 ◽  
Author(s):  
M. Baum ◽  
P.M. Ravdin

2006 ◽  
Vol 26 (6) ◽  
pp. 589-598 ◽  
Author(s):  
Edwin G. Wilkins ◽  
Julie C. Lowery ◽  
Laurel A. Copeland ◽  
Sherry L. Goldfarb ◽  
Patricia A. Wren ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document